MedTrace Logo

Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.

NCT03501680 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2018-06-06

No results posted yet for this study

Summary

The aim of this study is to investigate the therapeutic efficacy of intensive insulin in patients with hypertriglyceridemia induced moderate/severe acute pancreatitis on the course and outcome of disease.

Conditions

Interventions

DRUG

Insulin

Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis. Insulin was injected by insulin pump.

DEVICE

plasmapheresis

Triglyceridemia should be less than 5.65 mmol/l.

Sponsors & Collaborators

  • First Affiliated Hospital of Wenzhou Medical University

    lead OTHER

Principal Investigators

  • Meng-Tao Zhou, M.D. · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-06
Primary Completion
2020-03-08
Completion
2020-12-31
FDA Drug
Yes
FDA Device
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03501680 on ClinicalTrials.gov